Project Grant R01HL173308
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$698K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $815,510 to the University of Chicago to conduct research aimed at developing a genetic-based classifier to predict cancer patients' susceptibility to drug-induced cardiovascular toxicity. The research involves applying single-cell sequencing to cardiac guided differentiation cultures to study the effects of three anticancer drugs -...
This $2,454,955 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support research by the Beckman Research Institute of the City of Hope to investigate the integrative role of the RPS6KB1 protein in the pathological cardiac remodeling process that leads to heart failure. The research aims to elucidate the mechanisms by which RPS6KB1 regulates adaptive cardiac hypertrophy,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to uncover effective strategies for mitigating the detrimental effects of cardiac fibrosis in diseases like dilated cardiomyopathy (DCM). The $159,512 award will fund the validation and description of the anti-fibrotic mechanisms of two drug compounds, CGS15943 and AM404, in a mouse model of LMNA-related DCM. The research...
This $817,208 Project Grant was awarded on January 3, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research at the Broad Institute of MIT and Harvard to investigate the genetic basis and underlying mechanisms of heart failure (HF). The project will leverage high-throughput assays, including cell painting and Perturb-seq, to link genes associated with HF risk through genome-wide association...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,000,000 in funding to Novomedix LLC, a woman-owned small business in San Diego, California. The funding supports the development and validation of methods for analyzing the active pharmaceutical ingredient, as well as GLP toxicity and toxicology studies in rats and dogs, for a novel small molecule therapy that aims to protect against...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will support a $167,864 research study to investigate risk stratification and outcomes across the spectrum of immune checkpoint inhibitor (ICI) cardiotoxicity. The study aims to: Retrospectively examine cardiac and oncologic outcomes associated with ICI cardiotoxicity stratified by patient symptoms and troponin-I measurements....
This $1,102,957 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a comprehensive research effort to determine if cancer directly promotes cardiovascular disease and to identify potential therapies. The interdisciplinary research team at The Leland Stanford Junior University will combine population genetics, cardio-oncology, and translational medicine approaches to map causal associations and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the mechanisms by which mutations in the TET2 and IDH2 genes associated with acute myeloid leukemia (AML) disrupt cardiac metabolism and lead to cardiomyopathy. The $549,796 award to Cedars-Sinai Medical Center aims to examine how these AML-related genetic mutations impact oxidative metabolism, epigenetic...
This federal Project Grant award of $601,563 from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the pathogenic roles and molecular mechanisms of histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure (HF), with a focus on a specific type of hereditary cardiomyopathy known as lamin-associated dilated cardiomyopathy (LMNA-DCM). The research project, spanning...
This $149,948 Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of p53 signaling and endothelial-to-mesenchymal transition in the development of radiation-induced coronary heart disease. The project will utilize human-induced pluripotent stem cell (iPSC) models and transgenic mouse models to map gene regulatory network perturbations across different cell types...